{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 2
  },
  "completeness_stats": {
    "existing_evidence": 0,
    "new_evidence_found": 2,
    "total_evidence": 2
  },
  "verified_evidence": [],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "5. TreanorJJ, Schiff GM, Hayden fg, et.al. Safety and immunogen i city of aba culo virus expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "relevance_explanation": "This reference is to a published randomized controlled trial specifically evaluating the immunogenicity (antibody response) of a recombinant hemagglutinin influenza vaccine, which supports the claim that such vaccines may induce a robust antibody response.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "3 Keitel WA Tre an or JJ El Sahly HM et al Comparative immunogen i city of recom- nant influenza hemagglutinin (rHA) and trivalent in activated vaccines (TIVs) among rsons \u226565 years old Vaccine 2009 Vol 28 pp 379 385",
      "relevance_explanation": "This reference describes a comparative immunogenicity study between recombinant hemagglutinin (rHA) and standard trivalent inactivated vaccines (TIVs) in older adults, directly supporting the claim about differences in antibody response.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}